Business Wire

TRILIO

17.5.2022 13:08:04 CEST | Business Wire | Press release

Share
Trilio Announces Technical Preview of ‘Continuous Restore,’ Delivering Cloud-Native Application Portability and Recoverability in Seconds Across Disparate Infrastructure

KUBECON + CLOUDNATIVECON EUROPE— Trilio , a leading provider of cloud-native data protection, today announced a technical preview of a new “Continuous Restore” capability that is being showcased to the cloud-native community at the KubeCon + CloudNativeCon Europe conference. Continuous Restore offers faster levels of replication, restoration and migration of data and metadata from any storage or cloud platform to another, dramatically improving recovery times for cloud-native applications.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220517005514/en/

Entirely storage-, cloud- and distribution-agnostic, Trilio’s “Continuous Restore” capability will enable users to continuously stage data at multiple and heterogeneous clouds. This means that applications—regardless of where they reside—will be able to tap into that data and be brought online in seconds, achieving exceptional levels of Recovery Time Objectives (RTO). The capability will be introduced as part of the TrilioVault for Kubernetes cloud-native data protection and management platform.

“Distributed environments consisting of core, edge and cloud resources are becoming the predominant architecture for enterprises today,” said Murali Balcha, Founder and CTO of Trilio. “Companies frequently need to move stateful applications and their data volumes among these diverse environments to achieve cost-efficiency, performance, security and disaster recovery imperatives. Unfortunately, no easy-to-use, affordable solution for continuous data volume replication across heterogeneous infrastructure environments exists today.”

“Trilio’s Continuous Restore capability enables migration and replication of stateful applications in seconds or minutes so that all companies can protect and use their data anywhere—regardless of what the application runs on or where the data is stored,” continued Balcha. “This provides organizations the ability to meet leading levels of application uptime, achieve Service Level Agreements (SLAs) expected of production-grade applications—all at an affordable cost. Continuous Restore is a game-changer that will make today’s modern businesses even more competitive and resilient.”

***To see a Demo of Continuous Restore, visit Trilio at Booth P11 at KubeCon + CloudNativeCon Europe or schedule a meeting with our K8s Experts ***

Use cases for the Continuous Restore capability include:

1. Disaster Recovery: Users will be able to achieve availability objectives and recover from outages or failures in a matter of seconds or minutes rather than days or weeks. Using Continuous Restore, Recovery Time Objectives (RTO) will improve by over 80% versus traditional methods.

2. Application Migrations : Continuous Restore allows IT teams to optimize performance and achieve better Total Cost of Ownership (TCO) by choosing the infrastructure best suited to current needs. The Continuous Restore capability will also enable organizations to unify their infrastructure, especially those that have grown quickly and adopted a variety of compute platforms and storage solutions to meet unique needs. Continuous Restore will make possible tremendously fast application mobility across infrastructure silos, making them silos no more.

3. Testing/Development: Developers can increase the velocity of CI/CD pipelines by staging data for multiple test/dev environments. These test/dev environments can be spun up in seconds with continuously replicated production data and accelerating the push of validated changes into production. In fact, DevOps teams can use this capability to test their “restore” protocols to ensure that restore will work when needed.

4. Data Curation from Edge Clouds: As distributed environments proliferate in the future, massive amounts of data will be collected at “the edge,” and this information from diverse architectures will need to be rapidly replicated and moved throughout distributed systems where it can be assimilated and centrally analyzed by any number of different applications.

Attend Trilio’s Session: Cloud-Native App Recoverability & Portability in a Matter of Seconds thru the Unification of Information Silos'' on Thursday May 19 3pm CET at the Microsoft Azure Booth P12. Join Ben Morrison, solution architect at Trilio, for his presentation and demo showcasing Trilio's capability for migrating a stateful application from on-prem Red Hat OpenShift to Azure AKS in a matter of seconds — highlighting the flexibility and speed enabled by the TrilioVault for Kubernetes platform.

Continuous Restore is a capability within TrilioVault for Kubernetes and will be made generally available as part of a product release in Q3’22. For those that want to preview or test the capability, please contact Trilio .

About Trilio

Trilio is a leader in cloud-native data protection for Kubernetes, OpenStack and Red Hat Virtualization environments. Our TrilioVault technology is trusted by cloud infrastructure operators and developers for backup and recovery, migration and application mobility. Customers in telecom, defense, automotive and financial services leverage TrilioVault to recover from disasters, migrate workloads, move workloads to new infrastructure and migrate to new software distributions. Trilio.io , Twitter and LinkedIn .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye